CJC-1295 (No DAC) / GHRP-2 — 2 mg / 2 mg

This name describes a mixture rather than one molecule. The first component is generally marketed as modified GRF(1–29), a GHRH analogue with four amino-acid substitutions and no albumin-binding drug affinity complex. GHRP-2, also known as pralmorelin, is a separate synthetic growth-hormone secretagogue. The intended mechanistic pairing brings together GHRH-receptor signaling and the ghrelin/growth-hormone-secretagogue pathway to stimulate endogenous growth-hormone release. Umbrella Labs identifies the no-DAC component as modified GRF and distinguishes it from the longer-acting DAC form. [1]

Human endocrine research offers a related but not identical comparison. In older men and women, investigators reported that GHRP-2 combined with native GHRH stimulated growth-hormone secretion more than either stimulus alone; they also studied sustained hormonal responses to GHRP-2 separately. These measurements concern hormone secretion and IGF-related markers, not a clinical test of a retail CJC-no-DAC/GHRP-2 blend. [2] FDA’s 2024 review documents marketing of this particular multi-ingredient powder and notes incomplete chemical-form information in online listings. [3] Accordingly, its research description is a dual-pathway secretagogue combination; a seller’s blend ratio, chemical forms, or claims of longer-term body-composition effects cannot be inferred from the component names alone.